



8th Annual Meeting

October 21, 2023

7:00am – 8:00am	Registration and Breakfast
8:00am – 8:15am	Welcome
8:15am - 9:15am	BiTEs, CARs, and Much More: Updates in Multiple Myeloma (0.1 CEUs) – Dennis Marjoncu, PharmD, BCOP
9:15am – 10:15am	Enhancing Diversity in Oncology Clinical Trials: The Integral Role of Pharmacists (0.1 CEUs) – Camille Pope, PharmD, RPh
10:15am - 10:30am	BREAK
10:30am – 11:30am	Less is More. Or is it? Early vs Late Antibiotic De-Escalation in Febrile Neutropenia (0.1 CEUs) – Kori Holman, PharmD, BCOP / Dennis Marjoncu, PharmD, BCOP
11:30am – 12:00pm	The Rise of Early-Onset Colorectal Cancer: An Emerging Population (0.05 CEUs) – Sarah Cimino, PharmD, BCOP
12:00pm – 1:00pm	LUNCH
1:00pm – 1:15pm	TOPA Updates
1:15pm – 1:45pm	Recent Advances in Treatment: mTOR Inhibitors in Adult Sarcoma (0.05 CEUs) – Colleen McCabe, PharmD, BCOP
1:45pm – 2:45pm	New Drug Update (0.1 CEUs) – Mikala Hillis, PharmD, BCOP
2:45pm – 3:45pm	Approaches to Opioid Prescribing with High-Risk Behavior and Opioid Use Disorder in Oncology (0.1 CEUs) – Taylor Butler, PharmD, BCOP, BCPS
3:45pm – 4:00pm	BREAK
4:00pm – 5:00pm	Updates in Prostate Cancer (0.1 CEUs) – Carly Kesler, PharmD, BCOP
5:00pm – 6:00pm	The Use of Antifungals in Immunocompromised Patients (0.1 CEUs) – Pratish Patel, PharmD, BCIDP, AAHIVP
6:00pm – 6:05pm	Conclusion

Target Audience – This activity is primarily intended for pharmacists from all practice settings. No prerequisites required.

Educational Objectives:

Upon completion of these activities, the participant should be able to:

BiTEs, CARs, and Much More: Updates in Multiple Myeloma

UAN: 0064-9999-23-084-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Describe the pathophysiology of multiple myeloma.
2. Summarize the recent literature updates for agents in multiple myeloma.
3. Apply evidence-based recommendations to patient cases.

Enhancing Diversity in Oncology Clinical Trials: The Integral Role of Pharmacists

UAN: 0064-9999-23-085-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Define key terms related to clinical trial diversity, inclusive research, and health equity.
2. Describe current FDA guidance, legal requirements, and oncology organization recommendations related to improving participation of historically underrepresented racial and ethnic groups in clinical research.
3. Review trust-based frameworks for optimizing clinical trial diversity and outreach to historically underrepresented communities.
4. Recognize the role of pharmacists in advancing oncology clinical trial diversity efforts, based on various practice settings: community, health system, industry.

Less is More. Or is it? Early vs Late Antibiotic De-Escalation in Febrile Neutropenia

UAN: 0064-9999-23-086-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Review current guideline recommendations for the management of antibiotics in patients with febrile neutropenia (FN).
2. Summarize recent literature describing de-escalation strategies for antibiotics in patients with FN.
3. Apply evidence-based recommendations to patient cases.

The Rise of Early-Onset Colorectal Cancer: An Emerging Population

UAN: 0064-9999-23-087-L01-P (0.05 CEU)

Pharmacist Objectives:

1. Describe the role of mTOR inhibitors in the treatment of adult sarcoma.
2. Recognize how to manage common toxicities of mTOR inhibitors in adult sarcoma.

Recent Advances in Treatment: mTOR Inhibitors in Adult Sarcoma

UAN: 0064-9999-23-088-L01-P (0.05 CEU)

Pharmacist Objectives:

1. Identify the rationale and indications for NGS in cancer patients.
2. Describe the publicly available databases and resources available to evaluate NGS reports.
3. List which situations to use the available databases during the NGS evaluation.

New Drug Update

UAN: 0064-9999-23-089-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Identify newly FDA-approved medications.
2. Discuss the pharmacology of each new medication.
3. Review indications, adverse effects, and pertinent interactions.
4. Summarize supportive care measures and clinical pearls.
5. Discuss results of major clinical studies and place in therapy of each agent.

Approaches to Opioid Prescribing with High-Risk Behavior and Opioid Use Disorder in Oncology

UAN: 0064-9999-23-090-L01-P (0.1 CEU)

Pharmacist Objectives:

1. List strengths and weaknesses of monitoring oncology patients initiated on opioid therapy.
2. Discuss how to empathize and approach patients with concerning behavior.
3. Select analgesic options appropriate for individuals with high-risk opioid behaviors.

Updates in Prostate Cancer

UAN: 0064-9999-23-091-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Review recent clinical trial data and its impact on treating patients with prostate cancer.
2. Identify updates to the guidelines in the treatment of prostate cancer.
3. Discuss future horizons for the treatment of patients with prostate cancer.

The Use of Antifungals in Immunocompromised Patients

UAN: 0064-9999-23-092-L01-P (0.1 CEU)

Pharmacist Objectives:

1. Recall the prevalence of fungal infections in the immunocompromised population, including oncology patients, and the associated morbidity and mortality rates.
2. Describe the current antifungal agents available for the treatment and prevention of fungal infections in immunocompromised patients, including their mechanisms of action, spectrum of activity, and adverse effects.
3. Discuss recent changes in antifungal treatment guidelines, including the use of combination therapy, the duration of treatment, and the role of prophylaxis.
4. Identify controversies and unanswered therapeutic questions related to antifungal use in immunocompromised patients, such as the optimal management of breakthrough infections and the role of newer antifungal agents in clinical practice.
5. Analyze the emerging therapies with unique mechanisms of action for the treatment of invasive fungal infections, such as immunomodulatory agents, biofilm disruptors, and host-directed therapies.



Continuing Education Information – The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of these knowledge and application-based activities will provide a statement for up to 8 hours of CPE credit: 8 contact hours of credit (0.8 CEU). Successfully completing the activity and receiving credit includes: 1) reading the learning objectives and faculty disclosures; 2) participating in the educational activity; 3) evaluating the activity; and 4) completing all

self-assessment instruments and CE credit submission form. CE credit will be submitted to the NABP CPE monitor within 30 days. *It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.*

NABP e-PROFILE ID NUMBER: Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/>. To receive credit for your participation in this activity, all pharmacists must include their **CORRECT** NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in “rejected” status from the CPE Monitor. *It is the responsibility of the participant to notify The University of Tennessee (within the 60-day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.*

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Full Disclosure Policy Affecting CPE Activities – As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Planning Committee and Participating Faculty reported the following:

Planning Committee Faculty:

Allison Parisi, PharmD, BCOP, TOPA Continuing Education Chair

Mikala Hillis, PharmD, BCOP

Kori Holman, PharmD, BCOP

Nicholas Lockhart, PharmD, BCPS

Participating Faculty:

Dennis Marjoncu, PharmD, BCOP

Camille Pope, PharmD, RPh

Kori Holman, PharmD, BCOP

Sarah Cimino, PharmD, BCOP

Colleen McCabe, PharmD, BCOP

Mikala Hillis, PharmD, BCOP

Taylor Butler, PharmD, BCOP, BCPS

Carley Kesler, PharmD, BCOP

Pratish Patel, PharmD, BCIDP, AAHIVP

Financial disclosures:

Dr. Camille Pope has the following disclosures:

- Acclinate—salary and stock options
- AstraZeneca – salary and stock options

Dr. Sarah Cimino has the following disclosures:

- G1 Therapeutics – honorarium

Dr. Colleen McCabe has the following disclosures:

- Daiichi-sankyo – consultant fees

Dr. Pratish Patel has the following disclosures:

- VBI Vaccines – stock
- American Academy of HIV medicines – honorarium
- CME Outfitters – honorarium

No other speaking faculty or planning faculty reported any other disclosures. All of the relevant financial relationships listed for these individuals have been mitigated.

How to earn credit: Participants must complete the activity as described above in the Credit Designation Statement.

In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The presenters will inform the learner when they discuss or reference an unapproved, unlabeled, or investigational use of a therapeutic agent or biomedical device.

Disclaimer Statement: The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

Registration Fees: \$100-\$150 (member/non-member, early vs standard)